Detailed description page of THPdb

Details of Th1060 which contains 3 entries.

Entry 1
(1) Primary information
ID 1382
ThPP ID Th1060
Therapeutic Peptide/Protein Name Insulin, porcine
Sequence A chain: GIVEQCCTSICSLYQLENYCN; B chain: FVNQHLCGS view full sequnce in fasta
Functional Classification Ia
Molecular Weight 5795.6
Chemical Formula C257H387N65O76S6
Isoelectric Point 5.39
Hydrophobicity 0.298
Melting Point (℃) N.A.
Half Life N.A.
Description Insulin isolated from pig pancreas. Composed of alpha and beta chains, processed from pro-insulin. Forms a hexameric structure.
Indication/Disease For the treatment of type I and II diabetes mellitus.
Pharmacodynamics Insulin is used in the treatment of type I and type II diabetes. The primary activity of insulin is the regulation of glucose metabolism. In muscle and other tissues (except the brain), insulin causes rapid transport of glucose and amino acids intracellularly. It also promotes anabolism, and inhibits protein catabolism. In the liver, insulin promotes the uptake and storage of glucose in the form of glycogen, inhibits gluconeogenesis, and promotes the conversion of excess glucose into fat.
Mechanism of Action Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.
Toxicity N.A.
Metabolism Insulin is predominantly cleared by metabolic degradation via a receptor-mediated process.
Absorption N.A.
Volume of Distribution N.A.
Clearance N.A.
Categories Hypoglycemic Agents
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target Interferon alpha/beta receptor 2,Interferon alpha/beta receptor 1
Information of corresponding available drug in the market
Brand Name vetsulin
Company Intervet Inc (Merck Animal Health)
Brand Discription vetsulin is a sterile aqueous zinc suspension of purified porcine insulin.
Prescribed for vetsulinÂ (porcine insulin zinc suspension) is indicated for the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs and cats with diabetes mellitus
Chemical Name N.A.
Formulation purified porcine insulin 40 IU (35% amorphous and 65% crystalline), Zinc (as chloride) 0.08 mg, Sodium acetate trihydrate 1.36 mg, Sodium chloride 7.0 mg, Methylparaben (preservative) 1.0 mg, pH is adjusted with hydrochloric acid and/or sodium hydroxide.
Physcial Appearance VetsulinÂ is supplied as a sterile injectable suspension in multidose vials containing 10 mL of 40 IU/mL porcine insulin zinc suspension. Vials are supplied in cartons of one, 10 mL vial.
Route of Administration Subcutaneous Injection
Recommended Dosage In dogs: The initial recommended vetsulin dose is 0.5 IU insulin/kg body weight. Initially, this dose should be given once daily concurrently with, or right after a meal; In Cats:The initial recommended dose in cats is 1 to 2 IU per injection. The injections should be given twice daily at approximately 12 hour intervals.
Contraindication Dogs and cats known to have a systemic allergy to pork or pork products should not be treated with vetsulin. vetsulinÂ is contraindicated during periods of hypoglycemia.
Side Effects In dogs: Clinical signs of hypoglycemia were generally mild in nature (described as weakness, lethargy, stumbling, falling down, and/or depression, hematuria, vomiting, diarrhea, pancreatitis, non-specific hepatopathy/pancreatitis, development of cataracts, and urinary tract infections. In Cats: omiting, lethargy, diarrhea, decreased appetite/anorexia, pancreatitis, dermal events, respiratory disease, urinary tract disorder, renal disease, dehydration, weight loss, polydipsia, polyuria, behavioral change, and ocular discharge/conjunctivitis.
Useful Link http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=101642
PubMed ID 3053948, 3049614, 3330034, 3549531, 4280239
3-D Structure Th1060 (View) or (Download)

Entry 2
(2) Primary information
ID 1383
ThPP ID Th1060
Therapeutic Peptide/Protein Name Insulin, porcine
Sequence A chain: GIVEQCCTSICSLYQLENYCN; B chain: FVNQHLCGS view full sequnce in fasta
Functional Classification Ia
Molecular Weight 5795.6
Chemical Formula C257H387N65O76S6
Isoelectric Point 5.39
Hydrophobicity 0.298
Melting Point (℃) N.A.
Half Life N.A.
Description Insulin isolated from pig pancreas. Composed of alpha and beta chains, processed from pro-insulin. Forms a hexameric structure.
Indication/Disease For the treatment of type I and II diabetes mellitus.
Pharmacodynamics Insulin is used in the treatment of type I and type II diabetes. The primary activity of insulin is the regulation of glucose metabolism. In muscle and other tissues (except the brain), insulin causes rapid transport of glucose and amino acids intracellularly. It also promotes anabolism, and inhibits protein catabolism. In the liver, insulin promotes the uptake and storage of glucose in the form of glycogen, inhibits gluconeogenesis, and promotes the conversion of excess glucose into fat.
Mechanism of Action Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.
Toxicity N.A.
Metabolism Insulin is predominantly cleared by metabolic degradation via a receptor-mediated process.
Absorption N.A.
Volume of Distribution N.A.
Clearance N.A.
Categories Hypoglycemic Agents
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 3053948, 3049614, 3330034, 3549531, 4280240
3-D Structure Th1060 (View) or (Download)

Entry 3
(3) Primary information
ID 1384
ThPP ID Th1060
Therapeutic Peptide/Protein Name Insulin, porcine
Sequence A chain: GIVEQCCTSICSLYQLENYCN; B chain: FVNQHLCGS view full sequnce in fasta
Functional Classification Ia
Molecular Weight 5795.6
Chemical Formula C257H387N65O76S6
Isoelectric Point 5.39
Hydrophobicity 0.298
Melting Point (℃) N.A.
Half Life N.A.
Description Insulin isolated from pig pancreas. Composed of alpha and beta chains, processed from pro-insulin. Forms a hexameric structure.
Indication/Disease For the treatment of type I and II diabetes mellitus.
Pharmacodynamics Insulin is used in the treatment of type I and type II diabetes. The primary activity of insulin is the regulation of glucose metabolism. In muscle and other tissues (except the brain), insulin causes rapid transport of glucose and amino acids intracellularly. It also promotes anabolism, and inhibits protein catabolism. In the liver, insulin promotes the uptake and storage of glucose in the form of glycogen, inhibits gluconeogenesis, and promotes the conversion of excess glucose into fat.
Mechanism of Action Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.
Toxicity N.A.
Metabolism Insulin is predominantly cleared by metabolic degradation via a receptor-mediated process.
Absorption N.A.
Volume of Distribution N.A.
Clearance N.A.
Categories Hypoglycemic Agents
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target Hyaluronan,Transforming growth factor beta-1
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 3053948, 3049614, 3330034, 3549531, 4280241
3-D Structure Th1060 (View) or (Download)

OSDDlinux

Raghava's Group

IMTECH

CSIR

CRDD
CPPSITE 2.0

(1) Primary information
Entry 1
ID	1382
ThPP ID	Th1060
Therapeutic Peptide/Protein Name	Insulin, porcine
Sequence	A chain: GIVEQCCTSICSLYQLENYCN; B chain: FVNQHLCGS view full sequnce in fasta
Functional Classification	Ia
Molecular Weight	5795.6
Chemical Formula	C257H387N65O76S6
Isoelectric Point	5.39
Hydrophobicity	0.298
Melting Point (℃)	N.A.
Half Life	N.A.
Description	Insulin isolated from pig pancreas. Composed of alpha and beta chains, processed from pro-insulin. Forms a hexameric structure.
Indication/Disease	For the treatment of type I and II diabetes mellitus.
Pharmacodynamics	Insulin is used in the treatment of type I and type II diabetes. The primary activity of insulin is the regulation of glucose metabolism. In muscle and other tissues (except the brain), insulin causes rapid transport of glucose and amino acids intracellularly. It also promotes anabolism, and inhibits protein catabolism. In the liver, insulin promotes the uptake and storage of glucose in the form of glycogen, inhibits gluconeogenesis, and promotes the conversion of excess glucose into fat.
Mechanism of Action	Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.
Toxicity	N.A.
Metabolism	Insulin is predominantly cleared by metabolic degradation via a receptor-mediated process.
Absorption	N.A.
Volume of Distribution	N.A.
Clearance	N.A.
Categories	Hypoglycemic Agents
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	Interferon alpha/beta receptor 2,Interferon alpha/beta receptor 1
Information of corresponding available drug in the market
Brand Name	vetsulin
Company	Intervet Inc (Merck Animal Health)
Brand Discription	vetsulin is a sterile aqueous zinc suspension of purified porcine insulin.
Prescribed for	vetsulinÂ (porcine insulin zinc suspension) is indicated for the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs and cats with diabetes mellitus
Chemical Name	N.A.
Formulation	purified porcine insulin 40 IU (35% amorphous and 65% crystalline), Zinc (as chloride) 0.08 mg, Sodium acetate trihydrate 1.36 mg, Sodium chloride 7.0 mg, Methylparaben (preservative) 1.0 mg, pH is adjusted with hydrochloric acid and/or sodium hydroxide.
Physcial Appearance	VetsulinÂ is supplied as a sterile injectable suspension in multidose vials containing 10 mL of 40 IU/mL porcine insulin zinc suspension. Vials are supplied in cartons of one, 10 mL vial.
Route of Administration	Subcutaneous Injection
Recommended Dosage	In dogs: The initial recommended vetsulin dose is 0.5 IU insulin/kg body weight. Initially, this dose should be given once daily concurrently with, or right after a meal; In Cats:The initial recommended dose in cats is 1 to 2 IU per injection. The injections should be given twice daily at approximately 12 hour intervals.
Contraindication	Dogs and cats known to have a systemic allergy to pork or pork products should not be treated with vetsulin. vetsulinÂ is contraindicated during periods of hypoglycemia.
Side Effects	In dogs: Clinical signs of hypoglycemia were generally mild in nature (described as weakness, lethargy, stumbling, falling down, and/or depression, hematuria, vomiting, diarrhea, pancreatitis, non-specific hepatopathy/pancreatitis, development of cataracts, and urinary tract infections. In Cats: omiting, lethargy, diarrhea, decreased appetite/anorexia, pancreatitis, dermal events, respiratory disease, urinary tract disorder, renal disease, dehydration, weight loss, polydipsia, polyuria, behavioral change, and ocular discharge/conjunctivitis.
Useful Link	http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=101642
PubMed ID	3053948, 3049614, 3330034, 3549531, 4280239
3-D Structure	Th1060 (View) or (Download)

(2) Primary information
Entry 2
ID	1383
ThPP ID	Th1060
Therapeutic Peptide/Protein Name	Insulin, porcine
Sequence	A chain: GIVEQCCTSICSLYQLENYCN; B chain: FVNQHLCGS view full sequnce in fasta
Functional Classification	Ia
Molecular Weight	5795.6
Chemical Formula	C257H387N65O76S6
Isoelectric Point	5.39
Hydrophobicity	0.298
Melting Point (℃)	N.A.
Half Life	N.A.
Description	Insulin isolated from pig pancreas. Composed of alpha and beta chains, processed from pro-insulin. Forms a hexameric structure.
Indication/Disease	For the treatment of type I and II diabetes mellitus.
Pharmacodynamics	Insulin is used in the treatment of type I and type II diabetes. The primary activity of insulin is the regulation of glucose metabolism. In muscle and other tissues (except the brain), insulin causes rapid transport of glucose and amino acids intracellularly. It also promotes anabolism, and inhibits protein catabolism. In the liver, insulin promotes the uptake and storage of glucose in the form of glycogen, inhibits gluconeogenesis, and promotes the conversion of excess glucose into fat.
Mechanism of Action	Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.
Toxicity	N.A.
Metabolism	Insulin is predominantly cleared by metabolic degradation via a receptor-mediated process.
Absorption	N.A.
Volume of Distribution	N.A.
Clearance	N.A.
Categories	Hypoglycemic Agents
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	3053948, 3049614, 3330034, 3549531, 4280240
3-D Structure	Th1060 (View) or (Download)

(3) Primary information
Entry 3
ID	1384
ThPP ID	Th1060
Therapeutic Peptide/Protein Name	Insulin, porcine
Sequence	A chain: GIVEQCCTSICSLYQLENYCN; B chain: FVNQHLCGS view full sequnce in fasta
Functional Classification	Ia
Molecular Weight	5795.6
Chemical Formula	C257H387N65O76S6
Isoelectric Point	5.39
Hydrophobicity	0.298
Melting Point (℃)	N.A.
Half Life	N.A.
Description	Insulin isolated from pig pancreas. Composed of alpha and beta chains, processed from pro-insulin. Forms a hexameric structure.
Indication/Disease	For the treatment of type I and II diabetes mellitus.
Pharmacodynamics	Insulin is used in the treatment of type I and type II diabetes. The primary activity of insulin is the regulation of glucose metabolism. In muscle and other tissues (except the brain), insulin causes rapid transport of glucose and amino acids intracellularly. It also promotes anabolism, and inhibits protein catabolism. In the liver, insulin promotes the uptake and storage of glucose in the form of glycogen, inhibits gluconeogenesis, and promotes the conversion of excess glucose into fat.
Mechanism of Action	Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.
Toxicity	N.A.
Metabolism	Insulin is predominantly cleared by metabolic degradation via a receptor-mediated process.
Absorption	N.A.
Volume of Distribution	N.A.
Clearance	N.A.
Categories	Hypoglycemic Agents
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	Hyaluronan,Transforming growth factor beta-1
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	3053948, 3049614, 3330034, 3549531, 4280241
3-D Structure	Th1060 (View) or (Download)